rheumatoid arthritis

March 22, 2017March 22, 2017

Low RA Disease Activity Seen for 3 Years After Humira Stopped in Many Patients, Trial Shows

Results from a clinical trial revealed that patients with early rheumatoid arthritis (RA) who stopped taking Humira (adalimumab) once their RA was under control maintained a low disease activity for up to three ... Read more

March 20, 2017March 20, 2017

UCB Targets Rheumatoid Arthritis Patients in ‘Wellness 4U’ Program

News, rheumatoid arthritis

Rheumatoid arthritis (RA) patients are known to be at higher risk for cardiovascular and muscle problems. In this context, Belgian pharmaceutical giant UCB has developed the Wellness 4U health and wellness program to encourage ... Read more

March 17, 2017March 17, 2017

EULAR Recommends Use of JAK Inhibitors, Including Xeljanz, for RA Management

News, rheumatoid arthritis

The European League Against Rheumatism (EULAR) has recommended the use of janus kinase (JAK) protein inhibitors, such as Pfizer’s Xeljanz (tofacitinib citrate), for the management of rheumatoid arthritis (RA). EULAR’s recommendations ... Read more

March 15, 2017March 15, 2017

Namilumab Therapy Successful in Phase 1b Trial of Rheumatoid Arthritis

News, rheumatoid arthritis

Namilumab, an investigational monoclonal antibody that binds with high affinity to GM-CSF, shows promise in the treatment of rheumatoid arthritis (RA), new research shows. GM-CSF stands for “granulocyte macrophage colony-stimulating ... Read more

March 13, 2017March 13, 2017

Cases of RA-associated Pulmonary Hypertension Show Need for Timely Diagnosis

News, rheumatoid arthritis

A timely diagnosis and effective treatment strategy for patients with pulmonary hypertension (PH) associated with rheumatoid arthritis (RA) can prevent right heart failure and significantly enhance their quality of life, ... Read more

March 8, 2017March 8, 2017

Cytokine IL-21 Fuels Inflammation at Synovial Joints in RA Patients, Study Shows

News, rheumatoid arthritis

Scientists have discovered a group of immune cells that cause joint inflammation in rheumatoid arthritis (RA) by secreting a factor called interleukin (IL)-21 — a potential new target for RA therapeutics. The study ... Read more

March 6, 2017March 6, 2017

Transcript of Interview with Rheumatologist, Dr. Ara Dikranian

News, rheumatoid arthritis

Rheumatoid Arthritis News interviewed Dr. Ara Dikranian, a rheumatologist at the Cabrillo Center for Rheumatic Disease in El Cajon, California, about his experience in talking with rheumatoid arthritis (RA) patients concerning intimacy ... Read more

March 3, 2017March 3, 2017

Olumiant Improved RA Symptoms Better Than Humira, Study Finds

News, rheumatoid arthritis

Olumiant (baricitinib) improved patients’ outcomes in the treatment of moderate-to-severe rheumatoid arthritis (RA), in comparison to placebo and a current standard treatment, Humira (adalimumab). These findings were published in The New England ... Read more

March 1, 2017March 1, 2017

Truxima, Biosimilar of Rituximab, Approved in Europe for RA and Certain Cancers

News, rheumatoid arthritis

The European Commission approved Truxima as a biosimilar of rituximab (sold under the brand name Rituxan in the U.S.) in the EU for all indications approved for rituximab, including rheumatoid arthritis ... Read more

February 22, 2017February 22, 2017

Pfizer Reports Positive Results for Xeljanz as RA Therapy, When Combined with Methotrexate

News, rheumatoid arthritis

Pfizer recently announced top-line results from its Phase 3b/4 trial evaluating Xeljanz (tofacitinib citrate) as a treatment for moderate-to-severe rheumatoid arthritis (RA). The trial demonstrates that Xeljanz is more effective in ... Read more